by Prateek Chopra | June 29, 2026 | Diabetes Conferences | ADA 2026
Precision Medicine in T2D
- Personalized treatment selection may improve outcomes by identifying therapies most likely to benefit individual patients.
- This study expanded a validated treatment response prediction model to include both oral and subcutaneous semaglutide.
Methods
- Data were obtained from the UK Clinical Practice Research Datalink (CPRD Aurum).
- Non-insulin-treated individuals initiating semaglutide therapy through June 2024 were included.
- The primary outcome was change in HbA1c at 12 months.
- External validation was performed using the Scottish Diabetes Research Network (SDRN).
Study Population
- Oral semaglutide initiations: 3,056.
- Subcutaneous semaglutide initiations: 6,969.
- Mean baseline HbA1c: 74 ± 13 mmol/mol.
- Mean age: 59 ± 11 years.
- Mean BMI: 36 ± 7 kg/m².
- Mean eGFR: 93 ± 18 ml/min/1.73m².
- Male participants: 55%.
Model Performance
- HbA1c responses to oral semaglutide closely matched predictions derived from other GLP-1 receptor agonists.
- No model modification was required for oral semaglutide.
- Responses to subcutaneous semaglutide followed similar patterns but showed greater HbA1c reductions than predicted.
Key Findings
- Subcutaneous semaglutide achieved an additional HbA1c reduction of 7.0 mmol/mol (95% CI: 6.2–7.8) compared with other GLP-1 receptor agonists.
- An intercept adjustment improved model calibration for subcutaneous semaglutide.
- The revised model demonstrated excellent calibration during external validation in 2,951 semaglutide users from SDRN.
Clinical Implications
- The updated model can accurately estimate individual glycemic responses across multiple glucose-lowering therapies, including semaglutide.
- Such tools may support more personalized and evidence-based treatment selection in routine clinical practice.
The updated five-drug class prediction model accurately predicts HbA1c responses to both oral and subcutaneous semaglutide. Successful external validation supports its use as a precision medicine tool for individualized treatment selection in type 2 diabetes.